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1 ABSTRACT 
 
In this work three new macrocyclic gadolinium complexes (Gd-DO3A-ADA, Gd-DO3A-MAD 
and Gd-DO3A-APP) have been syntesised. This was done in order to study how the introduction 
of hydrophobic groups on DO3A affected the albumin binding and hence the T1-relaxivity. Gd-
DTPA was used as a control in the study. 
 
Gd-DO3A-MAD showed the highest degree of albumin binding (60%). Gd-DO3A-ADA did also 
have some affinity for albumin (19%) while Gd-DO3A-APP did not have any degree of albumin 
binding at all.  
 
The T1-relaxivity for all substances was close to 4.0mM-1 s-1 in a phosphate buffer solution (pH 
7.4). In a 4% BSA solution the T1-relaxivity increased for Gd-DO3A-MAD and Gd-DO3A-
ADA. Gd-DO3A-APP did not show any significant increase in the T1-relaxivity. 
 
It was attempt to displace Gd-DO3A-MAD from albumin by adding oxazepam, warfarin and 
caprylic acid to the solution. By adding caprylic acid to albumin before Gd-DO3A-MAD, a 
decrease in the T1-relaxivity was observed compared to the solution of only Gd-DO3A-MAD in 
albumin. 
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2 ABBREVIATIONS AND NOMENCLATURE 
 
2.1  Abbreviations 
 
   Chemical shift in ppm 
bs   Broad singlet 
BSA   Bovine serum albumin 
Cyclen   1,4,7,10-tetraazacyclododecane 
d   Dublett 
DO3A   1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan 
DTPA   Diethylentriaminepentaacetic acid 
EI   Electroionisation 
ES   Electrospray 
Gd-DO3A-ADA Gadolinium-1,4,7-Tris (carboxymethyl)- 10-[12-(2-acetamido) dodecanoic 
acid]- 1,4,7,10-tetraazacyclododecan 
Gd-DO3A-APP Gadolinium 1,4,7-Tris (carboxymethyl)- 10-[ (L)-2-(2-acetamido)-3-
phenyl-propanoic acid] - 1,4,7,10-tetraazacyclododecan 
Gd-DO3A-MAD Gadolinium 1,4,7-Tris (carboxymethyl)- 10-[ methyl 12-(2-acetamido) 
dodecanoate] - 1,4,7,10-tetraazacyclododecan 
Gd-DO3A-MAH Gadolinium-1,4,7-Tris (carboxymethyl)- 10-[ metyl-6(2-acetoxy) 
hexanoate]- 1,4,7,10-tetraaza-cyclododecan 
Gd-DO3A-MAP Gadolinium 1,4,7-Tris (carboxymethyl)- 10-[(L)-methyl 2-(2-acetamido)-
3-phenylpropanoate] - 1,4,7,10-tetraazacyclododecan 
HPLC High Performance Liquid Chromatography 
Hz   Hertz 
M   Molecule ion 
m   Multiplett 
Me   Methyl 
MRI   Magnetic resonance imaging 
MS   Mass spectrometry 
NMR   Nuclear magnetic resonance 
ppm   Parts per million 
Abbreviations and nomenclature 
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R1   Longitudal relaxations rate 
r1   Longitudal relaxivity 
s   Singlett 
t   Triplett 
T1   Longitudinal relaxation time 
T2   Transversal relaxation time 
Tert-butyl  1,1-dimetylethyl 
TFA   Triflouroacetic acid 
THF   Tetrahydrofuranone 
TLC   Thin layer chromatography 
q   Quartet 
 
2.2   Nomenclature 
 
The compounds are given their English names after the IUPAC-system for nomenclature.  
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3  INTRODUCTION 
 
3.1 Magnetic resonans imaging (MRI) 
 
3.1.1 Introduction 
In 1946, Felix Bloch and Edward Purcell independently discovered that the nuclei of different 
atoms absorbed radio waves at different frequencies1, 2. In 1952, Bloch and Purcell received the 
Nobel Prize for their discovery of what was referred to as Nuclear Magnetic Resonance (NMR), 
eventually to be known as Magnetic Resonance Imaging (MRI)3. In 1970, the medical imaging 
world significantly changed with the contributions of Dr. Raymond Damidian. Dr. Damidian 
discovered that the structure and abundance of water in the human body was the key to MR 
imaging. He showed that tumors' NMR signals differed from those of normal tissue. It was Paul 
Lauterbur, however, who implemented the concept of tri-plane gradients used for exciting 
selective areas of the body. In 1975 Peter Mansfield produced the first human NMR image4, 5. 
 
3.1.2 The basic principles of MRI 
Different tissues in the body have different density of hydrogen. MRI is, as mentioned, based on 
these hydrogen atoms. The protons in these atoms are constantly spinning around and because of 
that, creating a magnetic field (Figure 3.1). 
 
Figure 3.1: Proton spinning and creating a magnetic field 
Hydrogen nuclei magnetic moments are randomly oriented in the absence of an external 
magnetic field and are considered to have a net magnetization of zero. Once hydrogen protons 
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are placed in the presence of an external magnetic field, they align themselves parallel or anti-
parallel to the magnetic field. As more protons tend to aligned themselves parallel than anti-
parallel they do not cancel each other out (Figure 3.2).  
 
        
       No magnetic field   External magnetic field 
 
Figure 3.2: Protons in magnetic field and in no magnetic field 
 
Hydrogen atoms do not actually align directly with the direction of the magnetic field, but rather 
rotate around the axis of the magnetic field. This is called precession. The frequency of the 
precession is called the Larmor frequency and is important because it is the frequency at which 
the nucleus will absorb energy. The absorption of energy will cause the proton to alter its 
alignment. The precession frequency is dependent of the magnetic field and is described as 
follow: 
 
Wo=  × Bo 
 
Wo is the precession frequency,  is the gyromagnetic ratio (of hydrogen in MRI) and Bo is the 
strength of the magnetic field.  
 
If a radio wave pulse at the Larmor frequency is applied to the nucleus of a hydrogen atom, the 
protons will alter their alignment from the direction of the main magnetic field to the direction 
opposite the main magnetic field. The amount of applied energy will decide the deflection of the 
magnetization. When a 90° pulse is applied the protons will be flipped into the transversal plane. 
Introduction 
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After the external radio frequency signal is turned off, the system returns to equilibrium by a 
process called relaxation. Two phenomenon’s simultaneously occur.  
• Longitudinal magnetization gradually increases and is called T1 recovery  
• Transverse magnetization gradually decreases and is called T2 decay  
T1 recovery (also called spin-lattice relaxation) is described as the time it takes for 63% of the 
longitudinal magnetization to reappear, and T2 decay (also called spin-spin relaxation) is 
described as the time it takes before 63% of the transverse magnetic plane has disappeared. 
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3.2 MRI contrast agents 
3.2.1 Introduction 
The aim of using contrast agents in MRI is their affect on the relaxation times of the protons in 
the surrounding tissue. This was first published by Lauterbur, Mendoca-Dias and Rudin in 19786. 
They demonstrated that paramagnetic substances were effective enough that it could be 
visualized in MRI. The most abundant paramagnetic substances used today are Mn(), Gd() 
and Fe(). They all have high magnetic moments. Gd() is most common used in nowadays 
contrast agents because it has some favorable properties (see section 3.2.2). The Gd() ion 
cannot be used as a contrast agent itself because it is toxic. Therefore stabile complexes of the 
ion have to be prepared. Today 30-40% of all MRI investigations make use of a contrast agent7. 
3.2.2 Gadolinium based contrast agents 
Contrast agents based on gadolinium belongs to the group of positive contrast agents. That 
means they reduce the protons T1-relaxation time and because of that increase the signal intensity 
in MRI. Gd() is the most used paramagnetic ion in MRI. The most important reason is that 
Gd() has seven unpaired electrons, more than any other ion. Gd() also has a symmetric S-
state that will give a low electronic relaxation rate8. 
As earlier mentioned Gd() is a toxic heavy metal and therefore complexes have to be prepared. 
This complexes need to have a high stability to avoid in vivo dissociation and they have to be 
biocompatible. Good solubility in water and low osmolality are also preferred properties because 
the agents are used in quite large quantities. 
All current Gd() based MRI contrast agents on the European marked are based on either linear 
or macrocyclic poly(aminocarboxylat)-complexes.   
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3.2.3 Commercially available Gd() based MRI contrast agents 
There are currently six Gd() based MRI contrast agents on the Norwegian market. 
Table 3.1: Commercially available contrast agents on the Norwegian market.  
Product name Contrast agent Structure 
 
 
Dotarem® 
 
 
Gd-DOTA 
 
Gadolinium-1,4,7,10-tetra-acetic acid- 
1,4,7,10-tetraazacyclo-dodecane 
N
N
N
N
Gd3+
COO--OOC
-OOC COO-
 
 
 
Gadovist® 
Gd-DO3A-butrol 
 
Gadolinium-10-((hydroxymethyl)-2,3-
dihydroxypropyl)-1,4,7-triacetic acid-
1,4,7,10-tetreaza-cyclododecane 
N
N
N
N
Gd3+
COO--OOC
-OOC
OH
OH
OH
 
 
Magnevist® 
Gd-DTPA 
 
Gadolinium-N,N´,N´,N´´,N´´-
diethylentriaminepentaacetic acid 
-OOC N
N
N COO-
-OOC
-OOC COO-
Gd3+
 
 
 
 
MultiHance® 
Gd-BOPTA 
 
Gadolinium-(4RS)-(4-carboxy-5,8,11-
tris(carboxymethyl)-1-phenyl-2-oxa-
5,8,11-triazatridecan-13-oic acid) 
-OOC N
N
N COO-
-OOC
-OOC COO-
Gd3+
O
 
 
 
Omniscan® 
Gd-DTPA-BMA 
 
Gadolinium-N,N´´-bis(methyl-
carbamoylmethyl)-N,N´,N´´-tris- 
diethylentriamine-pentaacetic acid 
N
N
N
-OOC
Gd3+
COO- -OOC
H
N
H
N
O O
 
 
 
Prohance® 
Gd-HP-DO3A 
 
Gadolinium-10-(2-hydroxypropyl)-
1,4,7-triacetic acid-1,4,7,10-tetra-
azacyclododecane 
N
N
N
N
Gd3+
COO--OOC
-OOC
OH
 
 
 
Dotarem®, Gadovist®, Magnevist®, Omniscan® and Prohance® all have relatively similar 
properties. They are extracellular agents and they are excreted by glomerular filtration. They do 
not cross the intact blood-brain barrier and this make them well suited for diagnosis of 
pathologies in the brain. The T1-relaxivity of the contrast agents is relatively low. This is due to 
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the low R values and the complexes which can only bind one water molecule (The hydration 
number, q=1). 
MultiHance® is the only gadolinium based MRI contrast agent indicated for imaging of the liver. 
Because of its anionic and lipophilic properties it is taken up into the hepatocytes by the bilirubin 
anion system. The lipophilic group of MultiHance® has some affinity for albumin9. The bound 
part of the contrast agent will of that reason have increased R and again increased relaxivity.  
Table 3.2: Properties of gadolinium MRI contrast agents on the Norwegian market.  
Contrast 
agent 
Stability 
Log K 
Relaxivity 
(mM-1s-1) 
(25°C, 20MHz) 
Hydration 
number (q) 
R  (ps) m (ns) 
Dotarem® 25.38 4.28 18 778 1088 
Gadovist® 21.810 3.611 NA NA NA 
Magnevist® 22.58 4.38 18 588 1308 
MultiHance® 22.68 5.28 18 888 NA 
Omniscan® 16.98 4.48 18 668 10008 
Prohance® 23.88 3.7(40°C) 8 NA 57 NA 
 
3.2.5  New generation of MRI contrast agents 
The first gadolinium based MRI contrast agents introduced on the marked were unspecific in 
their distribution. The latest MRI contrast agent approved for the Norwegian marked is 
MultiHance®. As mentioned, this agent accumulates in the liver and is for that reason an 
organospecific contrast agent. Currently the phase III clinical trials are completed for another 
contrast agent, called AngioMARK® (MS-325) (Figure 3.3). This agent binds reversible to 
albumin and is well documented as a blood pool contrast agent. 
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-OOC N
N
N COO-
-OOC
-OOC COO-
Gd3+
O
P
O
-O O
 
Figure 3.3; AngioMARK®(MS-325) 
Lately, the research has begun focus on responsive MRI contrast agents. This means agents that 
alter their relaxivity as a function of alterations in the microenvironment whereby they distribute. 
This could be parameters such as pH, pO2, temperature or enzymatic activity12, 13, 14, 15.  
The trend in the development of new gadolinium based contrast agents can consequently be 
divided into two directions. The one is targeted compounds. This means contrast agents that will 
accumulate in a specific organ or area of the body. Especially contrast agents for the blood pool 
is well investigated. The second is responsive agents. Those are agents that alter their relaxivity 
because of the microenvironment whereby they distribute. The development of this class of 
contrast agents have not come as far as the targeted contrast agents, but it is expected that this 
field will continue to evolve. 
At last there are contrast agents that combine the two directions. This means contrast agents that 
are targeted towards an organ or area of the body and because of this increase their relaxivity. 
MS-325 is a compound in this class. It will because of binding upon albumin stay in the blood 
pool. This binding also makes it increase its relaxivity due to increased rotational correlation 
time. 
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3.3 Relaxivity 
MRI contrast agents are not directly visualized in the MR image. It is the effect of the complex 
on the nearby proton which is seen. The efficacy of a Gd() contrast agent is described by the 
T1-relaxivity (r1): 
( )[ ]ΙΙΙ
−
=
Gd
RR
r
mobs
11
1  
Where R1obs is the observed relaxation rate, R1m is the relaxation rate of the matrix and [Gd()] 
is the concentration of Gd() in mM. The T1-relaxation rate of hydrogen atoms in water 
containing gadolinium could be described from a model considering contribution from water 
molecules in the inner sphere, (water molecules coordinated to gadolinium, R1is), outer sphere 
(bulk water, R1os), second sphere (water attached to the ligand, R12s) and the diamagnetic 
contribution from the matrix, R1m . 
 
 R1obs= R1is+ R1os +R12s + R1m 
When one or more water molecules are coordinated to the gadolinium ion, R1is is the most 
important contribution to the T1-relaxation rate. R1is can be expressed as: 
 






+
=
MM
is
T
CqR
τ1
1
1
6,55
 
where C is the molar concentration of Gd(), q is the number of water molecule(s) coordinated 
to gadolinium, T1M is the longitudinal relaxation rate of the protons coordinated to gadolinium 
and M is the time the water molecule(s) is coordinated to gadolinium. The value of T1M is in turn 
given by the Solomon–Bloembergen-Morgan equation:
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

	




+
+
+
+
= 2
2
2
2
2
1
2
1
6
222
1 1
7
1
3)1(2
15
21
CS
C
CH
C
H
H
M r
SSg
T τω
τ
τω
τβγ
 
where H is the proton gyromagnetic ratio, g is the electron g-factor, S is the electron spin 
quantum number, ß is the Bohr magneton, rH is the distance between the Gd() ion and the inner 
sphere water protons, H and S are the proton and electron Larmor frequencies and ci (i= 1,2) 
are the correlation times related to the modulation of the electron-proton dipolar coupling. ci is a 
based on three factors: 
SMRCi ττττ
1111
++=  
where R is the reorientation of the paramagnetic species, M is the residence lifetime of the inner-
sphere water molecule and S is the electronic relaxation time to the Gd() ion. 
From this discussion it is seen that some parameters can be altered to affect the relaxivity. 
Increasing the hydrating number, increasing R or decreasing M will all involve increased 
relaxivity.  
Increasing the hydration number is often accompanied by a decrease in thermodynamic stability 
and kinetic inertness. This consequence is undesirable in a contrast agent. Increasing R has been 
a more successful way to increase the relaxivity. The preparation of macromolecules with 
covalent linked Gd() complexes, Gd() complexes which binds non covalent to endogenous 
macromolecules and multimeric Gd() chelates has been successfully in this way8.  
 
 
 
 
 
 
 
 
 
 
Aim of the study 
15 
4 AIM OF THE STUDY 
 
The aim of this study has been to synthesise DO3A-derivates with a high degree of albumin 
binding. Such substances have the potential as high relaxivity, blood pool agents. A contrast 
agent in this category is already designed and well documented, the previously mentioned MS-
325. MS-325 will, because of its high albumin binding, stay in the blood pool and do not diffuse 
into the extra cellular matrix in any degree. Because of that it will also has a much higher 
clearance time than the commercially available contrast agents. This will in time mean the 
substance is more exposed for degradation and therefore the complex has to be very stabile. 
From the literature it is known that macrocyclic complexes tend to be more stabile than linear 
complexes8, 16. The macrocyclic complexes have a much slower kinetic than the linear 
complexes and this makes the macrocyclic complexes exceptionally inert and thermo-
dynamically stable8. 
 
Another advantage of the DO3A derivates synthesized in this study is a more simple synthesis 
than MS-325. While MS-325 is a six step synthesis, the DO3A derivates synthesised here is a 3-
5 step synthesis17.  
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5 RESULTS AND DISCUSSION 
 
5.1 Strategies and synthesis of new MRI contrast agents 
 
 
N
N
N
N
O O
O
OH
HO
HO
O
O
O
O
N
N
N
N
O O
O
OHHO
HO
N
H
O
OH
O
N
N
N
N
O O
O
OHHO
HO
N
H
O
O
O
N
N
N
N
O O
O
OHHO
HO
N
H
O
O
O
N
N
N
N
O O
O
OHHO
HO
N
H
O
HO
O
Gd3+ Gd3+
Gd3+
Gd3+
Gd3+
Gd-DO3A-MAH
Gd-DO3A-MAD
Gd-DO3A-ADA
Gd-DO3A-MAP
Gd-DO3A-APP
 
 
Figure 5.1: Gd() complexes attempt to produce 
 
 
The aim of the study was to synthesise gadolinium-DO3A derivates with high degree of 
albumin binding. In this attempt different molecules with an assumed high affinity for 
albumin were coupled to DO3A. From the literature it is known that fatty acids have this 
quality18. Phenylalanine, like the fatty acids, also has a hydrophobic group and a hydrophilic 
part with a negative charge. NSAIDs and MS-325 which all have high protein binding, share 
these properties16, 19. It could therefore be expected that phenylalanine would have high 
affinity for albumin. It is known that a wide range of hydrofobic substances have high 
affinity for albumin and therefore the methyl esters of the acids were synthesised.  
 
The main strategy in the synthesis was to connect these substances with the secondary amine 
in DO3A (or DO3A-tert-butyl), using chloroacetyl chloride as a connecting link. 
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5.1.1 Synthesis of DO3A and DO3A-tert-butyl 
 
 
NH
NH
HN
HN
N
N
HN
N
O
O
O
O
O
O N
N
HN
N
O
O
O
OH
HO
HO
1 217
 
 
Figure 5.2: Synthesis of DO3A and DO3A-tert-butyl 
 
Synthesis of 1,4,7-tris(carboxymethyl-tert-butylester)-1,4,7,10-tetraazacyclodecane (DO3A-
tert-butyl)(1) 
The synthesis of DO3A-tert-butyl was carried out according to the litterature20. The yield (40%) 
was a little lower than expected. 13C-NMR and MS(ES+) confirmed the reaction had taken place 
and indicated a pure product.   
 
Synthesis of 1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclodecane (DO3A)(2) 
The tert-butyl groups of DO3A-tert-butyl had to be removed to give DO3A. This was carried out 
using TFA. TFA is often used for the cleavage of tert-butyl esters21. The yield of this reaction 
was 96%. 13C-NMR and MS(ES+) confirmed the reaction had taken place and indicated a pure 
product.   
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5.1.2 Strategy for synthesis of Gd-DO3A-MAH 
(Gadolinium-1,4,7-tris (carboxymethyl)- 10-[metyl-6(2-acetoxy)hexanoate]- 1,4,7,10 
-tetraazacyclododecan) 
 
 
O
O O
O
HO Cl
O
O
O
O
N
N
HN
N
O O
O
O
O
O
N
N
N
N
O O
O
O
O
O
O
O
O
O
N
N
N
N
O O
O
OH
HO
HO
O
O
O
O
+
3 4
1
56
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N
N
N
N
O O
O
OH
HO
HO
O
O
O
O
Gd3+
19
 
Figure 5.3: Strategy for synthesis of Gd-DO3A-MAH 
 
The synthesis strategy for DO3A-metyl-6(2-acetoxy)hexanoate was as described in figure 5.3. 
The reaction of DO3A-tert-butyl with alkyl halides is earlier described in the literature23. 
 
Synthesis of methyl-6-hydroxyhexanoate (3) 
The -caprolactone was reacted with methanol using concentrated sulfuric acid as a catalyst. 
After evaporation of the solvent, the oil was solved in water and neutralized by the addition of 
NaHCO3. There was no phase separation so the water was extracted with diethylether. After 
evaporation, TLC showed the substance was not pure so the oil was vacuum distilled. 1H-NMR, 
13C-NMR and MS(EI) confirmed the substance was synthesised. 
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Synthesis of methyl 6-(2-chloroacetoxy)hexanoate (4) 
The reaction between chloroacetyl chloride and primary alcohols is earlier described in the 
literature22. Triethylamine or K2CO3 is often used as a base to neutralize the HCl which is 
produced in the reaction. Both triethylamine and K2CO3 were tried in the attempt to synthesise 
methyl 6-(2-chloroacetoxy)hexanoate. K2CO3 was chosen because it made it easier to purify the 
substance and the yield tended to be higher. Flash chromatography on silica gave the product as 
a colorless oil and the yield was 91%. 1H-NMR, 13C-NMR, TLC and MS (EI) confirmed that the 
reaction had taken place and indicated a pure product. 
 
Synthesis of 1,4,7-tris (tert-butylcarboxymethyl)- 10-[ metyl-6(2-acetoxy)  hexanoate ] - 
1,4,7,10-tetraazacyclododecan (DO3A-tert-butyl-MAH)(5) 
Alkylation of DO3A-tert-butyl with alkyl halides is a widely used strategy for the preparation of 
DO3A derivates23. The reaction between DO3A-tert-butyl and methyl 6-(2-chloro-
acetoxy)hexanoate was carried out in acetonitrile in the presence of  K2CO3. The product was 
purified by flash chromatography and the yield was 23%. MS(ES+) confirmed the reaction had 
taken place and four signals could be observed in the specter; m/z = 701, 645, 589 and 533. This 
is the molecule ion and the dissociation of one too three of the tert-butyl groups. 13C-NMR 
showed the expected signals. The 1H-NMR-specter of the substance was more difficult to read, 
but it confirmed the right number of hydrogens.  
 
Synthesis of 1,4,7-tris (carboxymethyl)- 10-[ metyl-6(2-acetoxy)hexanoate]- 1,4,7,10-tetraaza-
cyclododecan (DO3A-MAH) (6) 
The cleavage of tert-butyl esters is performed using TFA (see section 5.1.1). DO3A-tert-butyl-
MAH was stirred in TFA and the solution was evaporated. The oil was solved in methanol and 
diethylether was added. The precipitate was filtered and washed with dietylether, but TLC and 
NMR indicated that the product was not pure. The substance was therefore submitted to flash 
chromatography on silica. MS(ES+) confirmed the substance. The 1H-NMR specter was not easy 
to interpret, but the integrals showed the right number of hydrogens. 13C-NMR showed the 
expected signals, except the signals for the carbons in the cyclen. It appears like they came as a 
broad, multiple, low signal. The reason for this may be the multizwitterion properties of the 
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substance. Some of the nitrogens would be protonated and some of them not. This will probably 
affect the signals of the nearby carbons and give the result as appeared her. 
 
Complexation of 1,4,7-tris (carboxymethyl)- 10-[ metyl-6(2-acetoxy) hexanoate]- 1,4,7,10-
tetraazacyclododecan with gadolinium (Gd-DO3A-MAH) (19) 
Complexation of the ligand was performed using GdCl3×6H2O. The reason GdCl3×6H2O was 
chosen and not Gd2O3 is that the complexation with Gd2O3 requires heating at 90-100°C over 
night. The stability of the complex under this condition was assumed to be low because the ester 
group which coordinated to gadolinium was exposed for hydrolysis. The disadvantage using 
GdCl3×6H2O is that you get an amount of inorganic salts in the product. The complexation was 
carried out according to the procedure in section 6.3 except this reaction was not heated. 
MS(ES+) and TLC showed that only a small amount of the ligand was complexed.  
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5.1.3 Strategy 1 for synthesis of Gd-DO3A-ADA 
(Gadolinium-1,4,7-tris (carboxymethyl)- 10-[12-(2-acetamido)dodecanoic acid]- 
1,4,7,10-tetraazacyclododecan) 
 
N
N
HN
N
O O
O
O
O
O
N
N
N
N
O O
O
O
O
O
N
H
O
N
N
N
N
O O
O
OH
HO
HO
N
H
O
H2N COOH N
H
COOH
Cl
O
COOHCOOH
20 7
1
218
+
N
N
N
N
O O
Ov
OHHO
HO
N
H
O
OH
O
Gd3+
22
 
Figure 5.4: Strategy for synthesis of Gd-DO3A-ADA 
 
It was attempt to use the same strategy to synthesize Gd-DO3A-ADA as was used for Gd-
DO3A-MAH. 
 
Synthesis of 12-(2-chloroacetamido)dodecanoic acid (7) 
This reaction procedure was about the same as the method used for the synthesis of methyl 6-(2-
chloroacetoxy)hexanoate. The problem was to find a solvent that would solve 12-
aminododecanoic acid and not react with chloroacetyl chloride. Dioxane, dichloromethane, 
aetonitrile and THF were tried. THF gave the best result and was chosen. The product was 
purified by flash chromatography on silica and the yield was 60%. MS(EI) and NMR confirmed 
the substance.  
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Synthesis of 1,4,7-tris (tert-butylcarboxymethyl)- 10[12-(2-acetamido)dodecanoic acid] - 
1,4,7,10-tetraazacyclododecan (DO3A-tert-butyl-ADA)(21) 
The reaction was carried out under the same conditions as for the synthesis of DO3A-tert-butyl-
MAH. TLC did not indicate that any reaction had occurred after 24 hours. The solvent was 
changed to chloroform, but no reaction occurred. The solvent was again changed to acetone and 
a small amount of NaI was added. There was still no reaction that occurred and therefore another 
strategy for the synthesis was chosen. 
 
5.1.4 Strategy 2 for synthesis of Gd-DO3A-ADA 
(Gadolinium-1,4,7-tris (carboxymethyl)- 10-[12-(2-acetamido)dodecanoic acid]- 
1,4,7,10-tetraazacyclododecan) 
 
N
N
HN
N
O O
O
OH
HO
HON
N
N
N
O O
O
OH
HO
HO
N
H
O
H2N COOH N
H
COOH
Cl
O
COOH
+
N
N
N
N
O O
O
OH
HO
HO
N
H
O
COOH
20 7
28
22
Gd3+
 
Figure 5.5: Strategy for synthesis of Gd-DO3A-ADA 
 
Because alkylation of DO3A-tert-butyl did not succeed it was tried to alkylate DO3A directly. 
Similar reactions between DO3A and alkyl halides have been carried out earlier24. 
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Synthesis of 1,4,7-tris (carboxymethyl)- 10[12-(2-acetamido)dodecanoic acid] - 1,4,7,10-
tetraazacyclododecan (DO3A -ADA)(8) 
Because it is a large difference in hydrofobicity between DO3A and 12-(2-acetamido) 
dodecanoic acid a solvent of methanol/ water had to be used. K2CO3 was added to neutralize HCl 
produced in the reaction and to provide that the secondary amine was not protonated. The 
product was evaporated in vacuum and submitted to flash chromatography on silica. The yield 
was 25%. NMR indicated the right product was synthesized. The signals for the carbons in the 
cyclen looked like the signals for the same carbons in DO3A-MAH (see synthesis of DO3A-
MAH for discussion). The other signals showed up as expected. The 1H-NMR specter was 
difficult to interpret. Anyway, integration of the signals gave the right number of protons. 
MS(ES+) confirmed the substance. 
 
Complexation of 1,4,7-tris (carboxymethyl)- 10[12-(2-acetamido)dodecanoic acid]- 1,4,7,10-
tetraazacyclododecan with gadolinium (Gd-DO3A-ADA) (22) 
DO3A-ADA was complexed with GdCl3×6H2O according to the procedure described in the 
experimental section. MS(ES+) confirmed the complexation had taken place. 
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 5.1.5 Strategy for synthesis of Gd-DO3A-MAD 
(Gadolinium 1,4,7-tris (carboxymethyl)- 10-[ methyl 12-(2-acetamido) dodecanoate] 
- 1,4,7,10-tetraazacyclododecan) 
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Figure 5.4: Strategy for synthesis of Gd-DO3A-MAD 
 
As the synthesis of Gd-DO3A-ADA was successful the synthesis of Gd-DO3A-MAD was 
performed much the same way. 
 
Synthesis of methyl-12-aminododecanoate (9) 
The synthesis of methyl esters from amino acids and methanol is well known in the litterature25. 
Thionyl chloride was slowly added to a cooled solution of 12-aminododecanoic acid and 
methanol. The solution was evaporated in vacuum and purified by flash chromatography on 
silica. The yield was 92%. NMR and MS(ES+) confirmed the substance. 
 
Synthesis of methyl 12-(2-chloroacetamido)dodecanoate (10) 
The synthesis was almost identical as for 12-(2-chloroacetamido)dodecanoic acid, except THF 
did not seem to be a good solvent. This was probably due to the increased hydrofobicity of 
methyl-12-aminododecanoate versus 12-aminododecanoic acid. Chloroform was chosen instead. 
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After filtration and evaporation the substance was purified by flash chromatography on silica. 
The yield was 62%. NMR and MS(ES+) confirmed the substance. 
 
Synthesis of 1,4,7-tris (carboxymethyl)- 10-[ methyl 12-(2-acetamido)dodecanoate] - 1,4,7,10-
tetraazacyclododecan (DO3A-MAD) (11) 
This step in the synthesis was almost parallel as for DO3A-ADA, except the base was switched 
to NaHCO3. The reason for this is that the high temperature and K2CO3 seemed to hydrolyse the 
methyl ester. The yield of the reaction (16%) was something lower than for DO3A-ADA. The 
reason for this may be the weaker base which would not deprotonate the secondary amine of 
DO3A in the same way as K2CO3. 13C-NMR for the substance was quite similar the specter for 
DO3A-ADA and contained in addition a clear signal for the carbon in the methyl ester group. 
1H-NMR was also almost identical to the specter for DO3A-ADA, but also here was the singlet 
from the hydrogens in the methyl ester group very clear. MS(ES+) confirmed the substance. 
 
 Complexation of 1,4,7-tris (carboxymethyl)- 10[methyl 12-(2-acetamido)dodecanoic acid]- 
1,4,7,10-tetraazacyclododecan with gadolinium (Gd-DO3A-MAD) (23) 
DO3A-ADA was complexed with GdCl3×6H2O according to the procedure described in the 
experimental section. MS(ES+) confirmed the complexation had taken place. 
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5.1.6 Strategy for synthesis of Gd-DO3A-APP 
(Gadolinium 1,4,7-tris (carboxymethyl)- 10-[ (L)-2-(2-acetamido)-3-phenyl-
propanoic acid] - 1,4,7,10-tetraazacyclododecan) 
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Figure 5.5; Strategy for synthesis of Gd-DO3A-APP 
 
The strategy for the synthesis of Gd-DO3A-APP was similar to the strategy used for Gd-DO3A-
MAD and Gd-DO3A-ADA. 
 
Synthesis of (L)-2-(2-chloroacetamido)-3-phenylpropanoic acid (12) 
The synthesis of (L)-2-(2-chloroacetamido)-3-phenylpropanoic acid has earlier been described in 
the literature26. Chloroacetyl chloride was added to a solution of L-phenylalanine and acetonitrile 
under nitrogen. The solution was put on reflux until it became clear. After evaporation of the 
acetonitrile, TLC did not indicate any impurities. NMR and MS(ES+) also indicated the right 
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substance was synthesized and indicated a pure product. No more work up of the substance was 
carried out. The yield was 100%. 
 
Synthesis of 1,4,7-tris (carboxymethyl)- 10-[ (L)-2-(2-acetamido)-3-phenylpropanoic acid] - 
1,4,7,10-tetraazacyclododecan ( DO3A-APP)(13) 
The reaction between DO3A and (L)-2-(2-acetamido)-3-phenylpropanoic acid was carried out in 
a solution of water, methanol and K2CO3. The solvent was evaporated off and the product was 
submitted to flash chromatography on silica, giving a yield of 56%. 13C-NMR showed the 
expected signals. The carbons in the cyclen appeared as described for DO3A-MAH. As for the 
other DO3A-derivates, either 1H-NMR for DO3A-APP was not easy to interpret. Anyway, 
integration of the specter showed the right number of hydrogens. MS(ES+) confirmed the 
substance.  
 
Complexation of 1,4,7-tris (carboxymethyl)- 10[(L)-2-(2-acetamido)-3-phenylpropanoic acid]- 
1,4,7,10-tetraazacyclododecan with gadolinium (Gd-DO3A-APP) (25) 
DO3A-APP was complexed with GdCl3×6H2O according to the procedure described in the 
experimental section. MS(ES+) confirmed the complexation had taken place. 
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5.1.7 Strategy for synthesis of Gd-DO3A-MAP 
(Gadolinium 1,4,7-tris (carboxymethyl)- 10-[(L)-methyl 2-(2-acetamido)-3-
phenylpropanoate] - 1,4,7,10-tetraazacyclododecan) 
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Figure 5.5; Strategy for synthesis of Gd-DO3A-MAP 
 
The strategy for the synthesis of Gd-DO3A-MAP was similar to the strategy used for Gd-DO3A-
MAD, Gd-DO3A-APP and Gd-DO3A-ADA. 
 
Synthesis of (L)-methyl-2-amino-3-phenylpropanoate(14) 
As earlier mentioned the synthesis of a methyl ester from an amino acid and methanol is well 
known in the litterature25. Thionyl chloride was slowly added to a cooled solution of L-
phenylalanine and methanol. The solution was evaporated in vacuum and purified by flash 
chromatography on silica and the yield was 93%. NMR and MS(ES+) confirmed the substance. 
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Synthesis of (L)-methyl 2-(2-chloroacetamido)-3-phenylpropanoate(15) 
Chloroacetyl chloride was added to a cooled solution of K2CO3 and (L)-methyl-2-amino-3-
phenylpropanoate in 25ml dichloromethane and 10ml acetonitrile. After stirring over night, the 
solution was filtered, evaporated in vacuum and purified by flash chromatography on silica. 
NMR and MS(ES+) confirmed the substance. The yield was 56%. 
 
Synthesis of 1,4,7-tris (carboxymethyl)- 10-[(L)-methyl 2-(2-acetamido)-3-phenyl-propanoate]- 
1,4,7,10-tetraazacyclododecan (DO3A-MAP)(16) 
The alkylation of DO3A was performed similar to the reaction used for the synthesis of DO3A-
MAD. TLC indicated that it was two substances in the end product, but it was not easy to see 
because of the relatively like retention time of the substances (0.47 versus 0.45). HPLC clearly 
showed a product consisting of two substances. The one had the same eluation time as DO3A-
APP. It did not succeed to purify the product, neither flashing on silica nor using an ion 
exchange column.   
 
Complexation of 1,4,7-tris (carboxymethyl)- 10-[(L)-methyl 2-(2-acetamido)-3-phenyl-
propanoate]- 1,4,7,10-tetraazacyclododecan with gadolinium (Gd-DO3A-MAP)(26) 
Even the DO3A-MAP was not pure it was complexed with GdCl3×6H2O according to the 
procedure described in the experimental section. MS(ES+) confirmed the complexation had taken 
place, but it also indicated that Gd-DO3A-APP was formed. 
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5.1.8 Complexation of DTPA with gadolinium 
 
Gd-DTPA was prepared from GdCl3 ×6H2O and diethylenetriaminepentaacetic acid as described 
in the experimental section. MS(ES+) confirmed the substance. 
 
5.1.9 Conclusion 
 
Three complexes have been prepared (Gd-DO3A-ADA, Gd-DO3A-MAD and Gd-DO3A-APP). 
One ligand (Gd-DO3A-MAH) has been synthesised and characterized but the complexation 
failed. Due to lack of time no more of the ligand was synthesized. The last ligand, Gd-DO3A-
MAP, was synthesised but it was not pure. The purification failed.  
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5.2 Binding to bovine serum albumin 
 
Albumin is a well known carrier for drugs and other small molecules. Its structure has been 
known since 197527. Albumin consist of a single peptide chain of 585 amino acids and has a 
molecular weight of approximately 66 300 Da27, 28. It is mostly -helical and consist of three 
structurally homologues domains and has a shape like a heart29. (Figure 5.6) 
 
 
Figure 5.6: Schematic structure of albumin 
 
The three domains can be further divided into subdomains A and B. Those subdomains are often 
used to explain were different binding sites on albumin are located. Sudlow et al have described 
two important sites which binds several drugs30, 31. Those principal regions of ligand binding to 
human serum albumin are located in hydrophobic cavities in subdomains IIA and IIIA32.  
Bhattacharya et al have described several binding sites for fatty acids18. 
 
5.2.1 Affinity for albumin 
The typical dose of a gadolinium based contrast agent injected is 0.1mmol/kg body weight. For 
two contrast agents, Magnevist and Gadovist, the plasma concentration will reach a maximum of 
respectively 2.0mM and 0.59mM19. The plasma concentration of albumin is 0.67mM. In the 
determination of the albumin binding it was desirable to keep the concentration of the complex 
lower than that of albumin. At the same time it was desirable to use a concentration that is close 
to plasma concentration of the contrast agents used today. A 0.50mM solution of the complexes 
was chosen. The albumin binding of Gd-DTPA was also tried to be measured, but it failed to 
develop a HPLC method for this substance. From the literature this value was found to be close 
to zero33. 
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The binding of the complexes Gd-DO3A-ADA, Gd-DO3A-MAD and Gd-DO3A-APP to 
albumin was measured.  
 
Table 5.1; Albumin binding of the Gd() complexes. 
Substance Parallel Albumin binding Average 
1 18.6 % 
2 18.4 % 
 
Gd-DO3A-ADA 
3 20.5 % 
 
19.2± 0.9 % 
1 -1.5 % 
2 0 % 
 
Gd-DO3A-APP 
3 -0.6 % 
 
0 % 
1 58.5 % 
2 61.8 % 
 
Gd-DO3A-MAD 
3 59.6 % 
 
60.0±1.4 % 
 
5.2.2 Conclusion 
The affinity upon albumin for the three complexes was measured. The methyl ester, Gd-DO3A-
MAD, had the highest affinity for albumin. Gd-DO3A-ADA also had a low degree of albumin 
binding, while Gd-DO3A-APP did not show any degree of binding at all.  
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5.3 Relaxivity 
 
Determinations of the T1–relaxivities of the Gd() complexes  were carried out in phosphate 
buffer solutions and in BSA, phosphate buffer solutions.  Gd-DTPA was used as a control. 
 
5.3.1 T1–relaxivities of the Gd() complexes. 
 
The T1–relaxivities (r1) (20MHz, 40°C, pH 7.4) of Gd-DO3A-ADA, Gd-DO3A-MAD and Gd-
DO3A-APP were measured. The results are summarized in table 5.2. 
 
Table 5.2; Relaxivity of the Gd() complexes. 
Substance  T1 (ms)  R1 (mM-1s-1) 
     
Phosphate  buffer pH 7.4 3000 3000 3000  
 
    
Gd-DTPA 10mM in buffer  26.9 27.8 27.1 3.63 
Gd-DTPA 25mM in buffer  9.5 10.2 10.5 3.96 
Gd-DTPA 25mM in albumin  8.0 8.4 8.0 4.90 
 
   
 
Gd-DO3A-ADA 10mM in buffer  22.7 25.3 24.8 4.09 
Gd-DO3A-ADA 10mM in albumin  16.9 16.8 17.1 5.87 
Gd-DO3A-ADA 20mM in albumin  8.5 8.8 8.8 5.73 
 
   
 
Gd-DO3A-APP 10mM in buffer  22.2 25.5 26.5 4.01 
Gd-DO3A-APP 10mM in albumin  23.0 24.2 23.4 4.22 
Gd-DO3A-APP 20mM in albumin  12.1 12.2 12.8 4.03 
 
   
 
Gd-DO3A-MAD 10mM in buffer  23.6 25.2 25.9 3.98 
Gd-DO3A-MAD 2.5mM in albumin  46.7 46.9 48.2 8.33 
Gd-DO3A-MAD 5mM in albumin  24.9 24.0 24.8 8.07 
Gd-DO3A-MAD 10mM in albumin  13.2 13.1 12.9 7.62 
 
   
 
Gd-DO3A-MAD 1.25mM in albumin 10% 48.2 47.8 47.7 16.47 
 
 
5.3.2 Conclusion 
The T1-relaxivity of the complexes has been measured. Gd-DTPA showed values which can be 
related to results in the literature8, 34, 35. Gd-DO3A-ADA, Gd-DO3A-MAD and Gd-DO3A-APP 
had relaxivities as expected. In the buffer solution all complexes had relaxivities close to 4.0 
mM-1s-1. From the literature, complexes of DO3A-derivates tend to have relaxivities close to this 
value8. As expected an increase in relaxivity was observed in the albumin solutions where the 
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complexes had any degree of albumin binding. From table 5.2 an increase in the relaxivity of 
Gd-DO3A-ADD and Gd-DO3A-MAD in albumin could be seen when the concentration of them 
decreased.  The assumed explanation for this is the excess of compounds in proportion to 
albumin in the solution. The ratio of bound and unbound gadolinium complex to albumin is 
increased when the concentration of the complexes decreases. 
 
5.4 Displacement 
 
As discussed in section 5.2, there are several binding sites on albumin. To confirm the protein 
binding of Gd-DO3A-MAD was the reason for the increased relaxivity, different substances that 
were expected to displace the complex were added to the HSA-complex solution and the 
relaxivity was measured. As described, two sites on subdomain IIA and IIIA binds a lot of drugs. 
Two drugs with high affinity for those sites are warfarin(IIA) and oxazepam(IIIA)27,36. Those 
were picked out. As the assumed protein binding part of the molecule, Gd-DO3A-MAD, is a 
fatty acid methyl ester, a fatty acid was also attempt as a displacer. If one of the two substances 
with a known binding site on albumin would involve a decreased relaxivity, this could also tell 
where the complex was bound. 
 
5.4.1 Relaxivity of Gd-DO3A-MAD with added displacers 
Two strategies were carried out in the attempt to displace Gd-DO3A-MAD. The first attempt 
was to add the displacers to a 2.5mM solution of Gd-DO3A-MAD in 4% BSA and measure the 
relaxivity. The second attempt was to first add the displacers to an 8% BSA solution and then 
add an equal volume of 5mM Gd-DO3A-MAD (making a final solution of 2.5mM Gd-DO3A-
MAD in 4% BSA) and measure the relaxivity. The substances added were warfarin, oxazepam 
and caprylic acid. The results are summarized in table 5.3 and 5.4 
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Strategy 1 
Table 5.3; Relaxivity of Gd-DO3A-MAD in albumin and with added substances 
Substance  T1 (ms)  R1 (mM-1s-1) 
 
   
 
Phosphate buffer pH 7.4 3000 3000 3000  
 
   
 
Gd-DO3A-MAD 2.5mM in albumin  46.9 48.6 48.3 8.21 
Gd-DO3A-MAD 2.5mM in albumin + oxazepam 5mM 47.8 47.9 46.7 8.29 
Gd-DO3A-MAD 2.5mM in albumin + warfarin 5mM 48.9 48.6 47.9 8.12 
Gd-DO3A-MAD 2.5mM in albumin + caprylic acid 5mM 48.5 48.6 48.0 8.14 
 
 
Strategy 2 
Table 5.4; Relaxivity of Gd-DO3A-MAD in albumin and with added substances 
Substance  T1 (ms)  R1 (mM-1s-1) 
 
   
 
Phosphate buffer pH 7.4 3000 3000 3000  
 
   
 
Gd-DO3A-MAD 2.5mM in albumin  46.7 46.9 48.2 8.33 
Gd-DO3A-MAD 2.5mM in albumin + oxazepam 5mM 46.4 47.6 45.8 8.45 
Gd-DO3A-MAD 2.5mM in albumin + warfarin 5mM 45.6 47.0 46.8 8.48 
Gd-DO3A-MAD 2.5mM in albumin + caprylic acid 5mM 79.5 80.3 80.5 4.86 
 
 
5.4.2 Conclusion 
In the first strategy it did not succeed to observe any decrease in the relaxation time. By using the 
second strategy a clear decrease in the relaxivity was seen when caprylic acid was added. This 
could indicate that Gd-DO3A-MAD binds to the same binding site as the caprylic acid. Another 
explanation may be that binding of caprylic acid to albumin could alter the structure of albumin, 
and of that reason prevent the binding of Gd-DO3A-MAD. 
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6 EXPERIMENTAL 
 
6.1 Chemicals and equipment 
 
6.1.1 Chemicals 
Chemicals were obtained from Aldrich Chemical Co.Inc.,USA, Fluka Chemie AG, Switzerland 
and Merck KGaA, Germany and used as received. 
 
6.1.2 Equipment 
NMR-spectra were obtained on Bruker Spectrospin Avance DPX 300 (Bruker GmbH, 
Germany). All spectra were recorded at 25°C. 
ES mass spectra were recorded on a Q-tof 2 (Micromass Ltd, UK). EI mass spectra were 
obtained at Fisions VG ProSpec Q, 70eV (Micromass Ltd, UK) 
Relaxation measurements were performed at 40°C and 20MHz on a Bruker Minispec mq 20 
NMR Analyzer (Bruker Analytik GmbH, Germany) 
HPLC analyses were performed on a Hewlett Packard 1100 instrument (Hewlett Packard GmbH, 
Germany). The column was a Phenomenax C-18 reversed phase (250mm×2mm, 5µm) and the 
detector was a diode UV detector (205 nm was used).  
 
6.1.3 Chromatography 
For analysis with TLC, TLC sheets with silica gel 60 F254 were used (DC-Alufolien 20×20 cm 
Kiselgel 60 F254, Merck). To recover the substances elementary iod or a solution of KMnO4 in 
water (1% w/w) were used. 
 
Silica gel 60 with particle size 0.04-0.063mm was used for flash chromatography. (Silica gel 60, 
Fluka)  
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6.2 Synthesis procedures 
 
1,4,7-tris(carboxymethyl-tert-butylester)-1,4,7,10-tetraazacyclodecane (DO3A-tert-butyl) 
N
N
HN
N
O O
O
OO
O
 
1 
 
Cyclen (35g, 0.20mol) and sodiumacetate (50g, 0.61mol) were dissolved in 600 ml dimethyl-
acetamide (DMA).  Bromoacetate (118.9g, 0.61mol) was solved in another 150 ml of DMA and 
added to the first solution. The mixture was stirred for 19 days at room temperature and the 
precipitate was then collected by filtration. The filtrate was concentrated to afford a second crop 
of the product. The combined crops were dissolved in chloroform and washed with water. The 
chloroform was evaporated off and the residue was a yellow oil. The addition of ethyl acetate to 
the oil gave a white solid which was collected by filtration and washed with ether. The yield was 
48.3g (40%).    
 
13C NMR (300MHz, CDCl3):  27.98, 28.01, 47.30, 48.93, 51.08, 57.93, 81.41, 169.39, 170.29 
 
MS (ES+) (Mw=514):  515 (M+H+), 459(M-C4H9), 403(M-2C4H9), 347(M-3C4H9)  
 
(NMR-specter: Appendix 1.1)   
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1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclodecane (DO3A) 
 
N
N
HN
N
COOH
COOH
COOH
 
2 
 
DO3A-tert-butyl (5.01g, 9.8mmol) was added 45 ml of triflouroacetic acid (600mmol). The 
solution was stirred at room temperature for 16 hours. The solvent was evaporated and the 
residue was solved in 10 ml of methanol. 100 ml diethyleter was slowly added under vigorous 
stirring. The precipitate was collected by filtration and washed with diethylether. The product 
was dried under vacuum. The yield was 96% (3.26g) 
 
13C NMR (300MHz, D2O):  42.96, 48.37, 49.64, 52.37, 53.82, 56.28, 170.45, 175.35 
 
MS (ES+) (Mw=346):  347 (M+H+) 
 
(NMR-specter: Appendix 1.2) 
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Methyl-6-hydroxyhexanoate 
 
O
O
HO
 
3 
 
2 ml 12 M H2SO4 was added dropwise to a stirred solution of -caprolactone (11.4g, 0.10mol) in 
250 ml methanol. The mixture was refluxed for 22 hours and then cooled to room temperature. 
The solvent was evaporated in vacuum. The residue was dissolved in 100ml water and 
neutralized with solid NaHCO3. The water was extracted with 4×25 ml diethyleter. Extracts was 
dried with MgSO4, filtered and evaporated. The residue was a colorless oil which was vacuum 
distilled (Boiling point 102-106°C and pressure 25mBar). The yield was 4.1g (28%). 
  
1H NMR (300MHz, CDCl3):  1.22-1.34 (m, 2H), 1.42-1.61 (m, 4H), 2.22 (t, 7.4 Hz, 2H), 2.38 
(s, 1H), 3.51 (t, 6.5 Hz, 2H), 3.56 (s, 3H) 
 
13C NMR (300MHz, CDCl3):  24.55, 25.21, 32.19, 33.90, 51.42, 62.41, 174.16 
 
MS (EI) (Mw=146):  146 (M), 128 (M-H2O) 
 
(NMR-specter: Appendix 2) 
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Methyl 6-(2-chloroacetoxy)hexanoate 
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A cooled solution of 10 ml dichloromethane was added chloroacetyl chloride (0.39g, 3.4mmol) 
and K2CO3 (0.62g, 4.5mmol). Methyl-6-hydroxyhexanoate (0.50g, 3.4mmol) was slowly dripped 
to the solution. The ice bath was removed and the solution stirred at room temperature for 2 
hours. The solution was then filtered and evaporated in vacuum. The residue was submitted to 
flash chromatography on silica (CH2Cl2:CHCl3, 1:1). The yield was 0.69g (91%) of a colorless 
oil. 
 
1H NMR (300MHz, CDCl3):  1.30-1.48 (m, 2H), 1.59-1.77 (m, 2H), 2.31 (t, 7.4 Hz, 2H), 3.66 
(s, 3H), 4.04 (s, 2H), 4.18 (t, 6.6 Hz, 2H) 
 
13C NMR (300MHz, CDCl3):  24.41, 25.30, 28.09, 33.77, 40.84, 51.48, 65.95, 167.29, 173.81 
 
MS (EI) (Mw=222):  222 (M), 187 (M-Cl) 
 
(NMR-specter: Appendix 3) 
 
 
 
 
 
 
 
 
 
Experimental 
41 
1,4,7-Tris (tert-butylcarboxymethyl)- 10-[ metyl-6(2-acetoxy)hexanoate]- 1,4,7,10-
tetraazacyclododecan 
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Metyl-6(2-chloroacetoxy)hexanoate (0.45g, 2mmol), DO3A-tert-butyl (0.89g, 1.5mmol) and 
K2CO3 (0.48g, 3.5mmol) was added to 15 ml acetonitrile. The solution was stirred at reflux for 
16 hours. The solution was filtered and the solvent was evaporated. The residue was submitted to 
flash chromatography on silica (CH2Cl2: MeOH: NH3 (25%), 8:2:0.1). The yield was 0.35g 
(23%) of a yellow oil.    
 
1H NMR (300MHz,CDCl3):  1.23-1.36 (m, 3H), 1.40 (s, 27H), 1.53-1.68 (m, 5H), 1.92-2.20 
(m, 3H), 2.22-2.31 (m, 4H), 2.32-2.61 (m, 5H), 2.63-3.49 (m, 
12H), 3.42 (s, 2H), 3.62 (s, 3H), 4.04 (t, 6.7 Hz, 2H) 
 
13C NMR (300MHz, CDCl3):  24.43, 25.43, 27.87, 27.95, 28.15, 28.21, 33.73, 51.49, 54.85, 
55.62, 55.68, 64.92, 81.86, 172.91, 172.99, 173.64, 173.76 
 
MS (ES+) (Mw=700):  701(M+H+), 645(M-C4H9), 589(M-C4H9), 533(M-C4H9) 
 
(NMR-specter: Appendix 4) 
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1,4,7-Tris (carboxymethyl)- 10-[ metyl-6(2-acetoxy)hexanoate]- 1,4,7,10-tetraaza-
cyclododecan 
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1,4,7-Tris (tert-butylcarboxymethyl)- 10-[ metyl-6(2-acetoxy)hexanoate]- 1,4,7,10-tetraaza-
cyclododecan (0.35g, 0.5mmol) was dissolved in 5 ml TFA. The solution was stirred at room 
temperature for 3 hours. The solvent was evaporated in vacuum and the residue (a yellow oil) 
was solved in 5 ml methanol. 50 ml diethylether was slowly added under severe stirring. After a 
while a white precipitate occurred. The solution was filtered on a schinter funnel and washed 
with diethylether. The white solid was then dried in vacuum and purified by flash 
chromatography on silica (MeOH: H2O: NH3 (25%), 9:1:0.1). The yield was 0.17g (66%).   
 
1H NMR (300MHz, D2O):  1.30-1.42 (m, 2H), 1.51- 1.73 (m, 4H), 1.78-3.33 (m, 23H), 3.33-
3.63 (m, 3H), 3.66 (s, 3H), 4.08-4.48 (m, 2H) 
 
13C NMR (300MHz, D2O):  24.32, 25.08, 27.73, 33.95, 48.45, 52.54, 53.13, 56.60, 59.14, 
59.40, 67.91, 177.90, 178.19, 180.23, 180.37 
 
MS (ES+) (Mw=532):  533 (M+H+) 
 
(NMR-specter: Appendix 5) 
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12-(2-chloroacetamido)dodecanoic acid 
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A solution of 12-aminododecanoic acid (0.43g, 2mmol) and K2CO3 (0.56g, 4mmol) in 15 ml 
terahydrofurane (THF) was cooled on an ice bath. Chloroacetyl chloride (165ml, 2mmol) was 
slowly added. The ice bath was removed and the solution was stirred at room temperature for 3 
hours. The solution was filtered and evaporated. The white solid that appeared was submitted to 
flash chromatography on silica (CH2Cl2: MeOH, 9:1) and the yield was 0.35g (60%) of a white 
solid. 
 
1H NMR (300MHz, CDCl3):  1.21-1.38 (m, 14H), 1.44-1.72 (m, 4H), 2.33 (t, 7.5 Hz, 2H), 3.30 
(q, 6.9 Hz, 2H), 4.07 (s, 2H), 6.62 (bs, 1H) 
 
13C NMR (300MHz, CDCl3):  24.65, 26.73, 28.96, 29.13, 29.24, 29.28, 29.35, 33.98, 39.93, 
42.66, 166.02, 179.36 
 
MS (EI) (Mw=291):  291 (M), 273 (M-H2O), 256 (M-Cl) 
 
(NMR-specter: Appendix 6) 
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1,4,7-Tris (carboxymethyl)- 10-[12-(2-acetamido)dodecanoic acid]- 1,4,7,10-tetraaza-
cyclododecan 
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12-(2-chloroacetamido)dodecanoic acid (1.00g, 3.43mmol), DO3A (1.00g, 2.89mmol) and 
K2CO3 (2.50g, 18.00mmol) was added to a solution of 30 ml water and 60 ml methanol. The 
solution was stirred at 60°C for 16 hours and then evaporated. The residue was purified by flash 
chromatography on silica (MeOH: H2O:NH3 (25%), 9:1:0.1). The yield was 0.44g (25%) of a 
white solid.    
 
1H NMR (300MHz, MeOD):  1.29 (s, 14H), 1.42-1.67 (m, 4H), 1.93-3.94 (m, 28H) 
 
13C NMR (300MHz, MeOD):  28.87, 28.15, 30.22, 30.41, 30.53, 30.61, 30.65, 36.96, 40.92, 
54.09, 58.21, 60.35, 60.46, 174.55, 179.58, 180.16, 180.25 
 
MS (ES+) (Mw=601):  602 (M+H+), 640 (M+K+) 
 
(NMR-specter: Appendix 7) 
 
 
 
 
 
 
 
Experimental 
45 
Methyl-12-aminododecanoate 
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12-aminododecanoic acid (0.86g, 4mmol) was solved in 25 ml methanol and cooled on an ice 
bath. SOCl2 (0.33ml, 4.3mmol) was slowly added under stirring. The ice bath was removed and 
the solution stirred overnight. The solvent was evaporated and the residue was submitted to flash 
chromatography on silica (CH2Cl2: MeOH: NH325%, 7:3:0.1). The yield was 0.84g (92%) of a 
white solid. 
 
1H NMR (300MHz, MeOD):  1.28-1.48 (m, 14H), 1.56-1.76 (m, 4H), 2.34 (t, 7.4 Hz, 2H), 2.95 
(t, 7.6 Hz, 2H), 3.68 (s, 3H) 
 
13C NMR (300MHz, MeOD):  26.05, 27.49, 28.61, 30.21, 30.24, 30.38, 30.49, 30.57, 34.83, 
40.83, 52.00, 176.01 
 
MS (ES+) (Mw=229):  230 (M+H+) 
 
(NMR-specter: Appendix 8) 
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Methyl 12-(2-chloroacetamido)dodecanoate 
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Methyl 12-dodecanoate (0.46g, 2mmol) was dissolved in 15 ml chloroform and K2CO3 (0.28g, 
2mmol) was added. The solution was cooled on an ice bath and chloroacetyl chloride (165ml, 
2mmol) was slowly added. The ice bath was removed and the solution was stirred at room 
temperature for 2 hours. The solution was filtered and evaporated. The white solid that appeared 
was purified by flash chromatography on silica (Hexane: Ethylacetate, 6:4) and the yield was 
0.38g (62%) of a white solid. 
 
1H NMR (300MHz, CDCl3):  1.23-1.35 (m, 14H), 1.47-1.70 (m, 4H), 2.30 (t, 7.5 Hz, 2H), 3.30 
(q, 7.1 Hz, 2H), 3.66 (s, 3H), 4.08 (s, 2H) 
 
13C NMR (300MHz, CDCl3):  24.91, 26.74, 29.09, 29.17, 29.33, 29.39, 34.09, 40.06, 42.55, 
51.47, 166.44, 174.48 
 
MS (ES+) (Mw=305):  306 (M+H+) 
 
(NMR-specter: Appendix 9) 
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1,4,7-Tris (carboxymethyl)- 10-[ methyl 12-(2-acetamido)dodecanoate] - 1,4,7,10-
tetraazacyclododecan 
 
N
N
N
N
O O
O
OHHO
HO
N
H
O
O
O
 
11 
 
Methyl 12-(2-chloroacetamido)dodecanoate (0.46g, 1.5mmol), DO3A (0.52g, 1.5mmol) and 
NaHCO3 (0.63g, 7.5mmol) was dissolved in 10 ml water and 20 ml methanol. The solution was 
stirred at 70°C for 16 hours and the solvent was evaporated. The residue was submitted to flash 
chromatography on silica (MeOH: H2O: NH3 (25%), 9:1:0.1). The yield was 0.15g (16%) of a 
white solid.    
 
 
1H NMR (300MHz, D2O):  1.28 (s, 14H), 1.41-1.67 (m, 4H), 1.98-3.64 (m, 28H), 3.66 (s, 
3H) 
 
13C NMR (300MHz, D2O):  26.45, 28.24, 30.22, 30.47, 30.64, 30.84, 30.89, 35.74, 41.59, 
49.97, 53.96, 54.29, 58.98, 60.71, 60.86, 175.56, 178.88, 181.98 
 
MS (ES+) (Mw=615):  616 (M+H+), 638 (M+Na+) 
 
(NMR-specter: Appendix 10) 
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(L)-2-(2-chloroacetamido)-3-phenylpropanoic acid 
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L-phenylalanine (0.50g, 3.0mmol) was added to 10 ml acetonitrile under nitrogen. Chloroacetyl 
chloride (253ml, 3.1mmol) was added and the solution was put on reflux until the solution 
became clear. The solvent was evaporated and a yellow oil appeared. The oil crystallized after a 
while and the yield was 0.72g (100%)  
 
 
1H NMR (300MHz, MeOD):  2.89-3.00 (q, 8.4 Hz, 1H), 3.10-3.20 (q, 5.1Hz, 1H), 3.93 (s, 2H), 
4.57-4.64 (q, 5.1Hz, 1H), 7.09-7.24 (m, 5H) 
 
13C NMR (300MHz, MeOD):  38.19, 42.95, 55.29, 127.93, 129.50, 130.35, 138.06, 168.92, 
174.03 
 
MS (ES+) (Mw=241):  242 (M+H+) 
 
(NMR-specter: Appendix 11) 
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1,4,7-Tris (carboxymethyl)- 10-[(L)-2-(2-acetamido)-3-phenylpropanoic acid]- 1,4,7,10-
tetraazacyclododecan 
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2-(2-chloroacetamido)-3-phenylpropanoic acid (0.96g, 4mmol), DO3A (1.38g, 4mmol) and 
K2CO3 (3.34 g, 24mmol) was dissolved in 10 ml water and 20 ml methanol. The solution was 
stirred at reflux for 16 hours and the solvent was evaporated. The residue was submitted to flash 
chromatography on silica (MeOH: H2O: NH3 (25%), 9:1:0.1). The yield was 1.23g (56%) of a 
white solid.    
 
1H NMR (300MHz, D2O):  1.36-3.01 (m, 22H), 3.18 (s, 2H), 3.24-3.60 (m, 2H), 4.37-4.53 
(m, 1H), 7.05-7.25 (m, 5H) 
 
13C NMR (300MHz, D2O):  37.54, 47.23, 51.92, 55.79, 56.12, 57.98, 58.43, 126.18, 128.22, 
128.65, 137.75, 172.45, 177.11, 178.78, 179.39 
 
MS (ES+) (Mw=551):  552 (M+H+), 574 (M+Na+), 590 (M+K+) 
 
(NMR-specter: Appendix 12) 
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(L)-Methyl-2 amino-3-phenylpropanoate 
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L-phenylalanine (2.07g, 12.5mmol) was solved in 25 ml methanol and cooled on an ice bath. 
SOCl2 (1.0ml, 13.0mmol) was slowly added under stirring. The ice bath was removed and the 
solution stirred overnight. The solvent was evaporated and the residue was submitted to flash 
chromatography on silica (CH2Cl2: MeOH, 9:1). The yield was 2.05g (93%) of a white solid. 
 
1H NMR (300MHz, CDCl3):  1.57 (s, 2H), 2.76-2.89 (q, 7.9 Hz, 1H), 2.88-3.11 (q, 5.1 Hz, 
1H), 3.66 (s, 3H), 3.67-3.74 (m, 1H), 7.10-7.32 (m, 5H) 
 
13C NMR (300MHz, CDCl3):  40.93, 51.81, 55.67, 126.69, 128.42, 129.12, 137.07, 175.25 
 
MS (ES+) (Mw=179):  180 (M+H+) 
 
(NMR-specter: Appendix 13) 
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(L)-Methyl 2-(2-chloroacetamido)-3-phenylpropanoate 
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(L)-methyl-2 amino-3-phenylpropanoate (0.50g, 2.8mmol) and K2CO3 (0.78g, 5.6mmol) was 
added to a solution of 25 ml dichloromethane and 10 ml acetonitrile. The solution was cooled on 
an ice bath and chloroacetyl chloride (231ml, 2.8mmol) was slowly added. The ice bath was 
removed and the solution was stirred at room temperature for 2 hours. The solution was filtered 
and evaporated. The residue was submitted to flash chromatography on silica (CH2Cl2: THF, 
9:1). The yield was 0.40g (56%) of a colorless oil. 
 
1H NMR (300MHz, CDCl3):  2.97-3.15 (m, 2H), 3.66 (s, 3H), 3.94 (s, 2H), 4.73-4.84 (m, 1H), 
6.98-7.30 (m, 5H) 
 
13C NMR (300MHz, CDCl3):  37.74, 42.33, 52.44, 53.35, 127.30, 128.65, 129.16, 135.28, 
165.54, 171.20 
 
MS (ES+) (Mw=255):  256 (M+H+) 
 
(NMR-specter: Appendix 14) 
 
 
 
 
 
 
Experimental 
52 
1,4,7-Tris (carboxymethyl)- 10-[(L)-methyl 2-(2-acetamido)-3-phenylpropanoate]- 1,4,7,10-
tetraazacyclododecan 
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(L)-methyl 2-(2-chloroacetamido)-3-phenylpropanoate (0.40g, 1.57mmol), DO3A (0.54g, 
1.57mmol) and NaHCO3 (0.66g, 7.86mmol) was dissolved in 10 ml water and 20 ml methanol. 
The solution was stirred at reflux for 16 hours and the solvent was then evaporated. The residue 
was submitted to flash chromatography on silica (MeOH: H2O: NH3 (25%), 9:1:0.1). The yield 
was 0.22g (24%) of a white solid.    
 
1H NMR (300MHz, D2O):  1.30-3.90 (m, 29H), 4.45-4.60 (m, 1H), 7.10-7.33 (m, 5H) 
 
13C NMR (300MHz, D2O):  37.58, 47.26, 51.88, 52.41, 55.89, 56.12, 57.99, 58.45, 126.17, 
128.22, 128.65, 137.81, 172.45, 177.24, 178.81, 179.35, 179.43 
 
MS (ES+) (Mw=565):  566 (M+H+) 
 
(NMR-specter: Appendix 15) 
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6.3 Preparation of Gd() complexes 
 
The ligand and GdCl3× 6H2O were dissolved in water (10 ml) in equal amounts. The pH was 
adjusted to pH 7.0 by the addition of aqueous sodium hydroxide and the solution was stirred at 
50°C for 2 hours. The pH was then adjusted to 9 by the addition of aqueous sodium hydroxide. 
The solution was filtered and the filtrate was evaporated. 
 
Gd-DTPA was prepared by another method. GdCl3× 6H2O (1.86g, 0.50mol) was solved in 20 ml 
water. The pH was adjusted to 11 by the addition of 5M NaOH. The solution was sentrifugated 
and the precipitate was washed with water until pH became neutral. The precipitate was 
transferred to a flask and 100 ml water and DTPA was added (1.98g, 0.50mol). The pH was 
adjusted to 7 by the addition of aqueous sodium hydroxide and the solution was refluxed until it 
became clear. At last the water was evaporated and the product was dried in vacuum. 
 
6.4 Determination of albumin binding 
 
Standard solutions of 1 mmol/ml Gd-DO3A-ADA, Gd-DO3A-MAD and Gd-DO3A-APP in 
phosphate buffer pH 7.4 were prepared. From each of those solutions two samples were made; 
One consisting of 1 ml standard solution and 1 ml phosphate buffer pH 7.4. The other consist of 
1 ml standard solution and 1 ml 8% BSA. The samples were heavy stirred and put on a water 
bath at 37°C for 1 hour. Before the samples were filtered, a small amount of the phosphate buffer 
solution was taken out as a control to see if some of the substances were lost during the filtration. 
The samples were then transferred to Centricon filters (Centrifugal filter devices 10 000 Mw cut 
off) and sentrifugated at 37°C for 1 hour (4000 rpm). After sentrifugation the concentration of 
unbound substance in filtrate was determined on HPLC. The HPLC method used was an 
isocratic eluation consisting of acetonitrile in aqueous H3PO4, pH 2.1. The flow rate was 0.6 
ml/min. The albumin binding was measured three times for each substance. 
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6.5 Determination of T1- relaxivity 
The substances Gd-DO3A-ADA, Gd-DO3A-MAD and Gd-DO3A-APP were prepared at 
concentrations from 1.25mM to 20mM in phosphate buffer- and BSA-solutions. The relaxation 
time was measured at 40°C. BSA solutions were 4% BSA in phosphate buffer pH 7.4 (in one 
measurement a 10% BSA solution was used to make a 1:1 ratio between albumin and the 
complex). Relaxation time of DTPA-Gd was measured and used as a control. The T1- relaxivity 
of the complexes was calculated from the following equation:  
( )[ ]ΙΙΙ
−
=
Gd
RR
r
mobs
11
1  
where R1obs is the observed relaxation rate which in time is 1/ T1obsand R1m is the relaxation rate 
of the matrix which in time is 1/T1m. [Gd()] is the concentration of Gd() in mM. 
 
6.6 Displacement 
 
In the first strategy a 2.5mM solution of Gd-DO3A-MAP in BSA was prepared. 16ml of this 
solution was equally divided into four test tubes. The first was added an amount of oxazepam to 
give a concentration of 5mM. The second was added an amount of warfarin to give a 
concentration of 5mM, and the third was added an amount of caprylic acid to give a 
concentration of 5mM. The last was used as a control. The relaxation was measured for each of 
those test tubes. 
 
In the second strategy a 5mM solution of Gd-DO3A-MAP and an 8% solution of BSA was 
prepared, both in phosphate buffer pH 7.4. Four test tubes were added 2ml of the BSA solution 
and the substances warfarin, oxazepam and caprylic acid was each added to one test tube to give 
a concentration at 10mM. The albumin solutions with the added substances were stirred and 2ml 
of the Gd-DO3A-MAP were added to each tube. The tubes were stirred again and the relaxivity 
was measured. If any of the added substances would displace Gd-DO3A-MAP from BSA, a 
decrease in the relaxivity was expected. 
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8 APPENDICES 
 
Appendix 1: 13C NMR of 1,4,7-tris(carboxymethyl-tert-butylester)-1,4,7,10-
tetraazacyclodecane (DO3A-tert-butyl) 
13C NMR of 1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclodecane (DO3A) 
 
Appendix 2:  13C NMR and 1H NMR of methyl-6-hydroxyhexanoate 
 
Appendix 3: 13C NMR and 1H NMR of methyl 6-(2-chloroacetoxy)hexanoate 
 
Appendix 4: 13C NMR and 1H NMR of 1,4,7-tris (tert-butylcarboxymethyl)- 10-[ metyl -6(2-
acetoxy)hexanoate]- 1,4,7,10-tetraazacyclododecan 
 
Appendix 5: 13C NMR and 1H NMR of 1,4,7-tris (carboxymethyl)- 10-[ metyl-6(2-
acetoxy)hexanoate]- 1,4,7,10-tetraazacyclododecan 
 
Appendix 6: 13C NMR and 1H NMR of 12-(2-chloroacetamido)dodecanoic acid 
 
Appendix 7: 13C NMR and 1H NMR of 1,4,7-tris (carboxymethyl)- 10-[12-(2-
acetamido)dodecanoic acid]- 1,4,7,10-tetraazacyclododecan 
 
Appendix 8: 13C NMR and 1H NMR of methyl-12-aminododecanoate 
 
Appendix 9: 13C NMR and 1H NMR of methyl 12-(2-chloroacetamido)dodecanoate 
 
Appendix 10: 13C NMR and 1H NMR of 1,4,7-tris (carboxymethyl)- 10-[ methyl 12-(2-
acetamido)dodecanoate] - 1,4,7,10-tetraazacyclododecan 
 
Appendix 11: 13C NMR and 1H NMR of (L)-2-(2-chloroacetamido)-3-phenylpropanoic acid 
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Appendix 12: 13C NMR and 1H NMR of 1,4,7-tris (carboxymethyl)- 10-[(L)-2-(2-acetamido)-3-
phenylpropanoic acid]- 1,4,7,10-tetraazacyclododecan 
 
Appendix 13: 13C NMR and 1H NMR of (L)-methyl-2-amino-3-phenylpropanoate 
 
Appendix 14: 13C NMR and 1H NMR of (L)-methyl 2-(2-chloroacetamido)-3-phenyl-
propanoate 
 
Appendix 15: 13C NMR and 1H NMR of 1,4,7-tris (carboxymethyl)- 10-[(L)-methyl 2-(2-
acetamido)-3-phenylpropanoate]- 1,4,7,10-tetraazacyclododecan 
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Appendix 1 
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Methyl-6-hydroxyhexanoate 
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Methyl 6-(2-chloroacetoxy)hexanoate 
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1,4,7-Tris (tert-butylcarboxymethyl)- 10-[ metyl-6(2-acetoxy)hexanoate]- 1,4,7,10-
tetraazacyclododecan 
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1,4,7-Tris (carboxymethyl)- 10-[ metyl-6(2-acetoxy)hexanoate]- 1,4,7,10-tetraaza-
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12-(2-Chloroacetamido)dodecanoic acid 
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1,4,7-Tris (carboxymethyl)- 10-[12-(2-acetamido)dodecanoic acid]- 1,4,7,10-tetraaza-
cyclododecan 
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Methyl-12-aminododecanoate 
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Methyl 12-(2-chloroacetamido)dodecanoate 
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1,4,7-Tris (carboxymethyl)- 10-[ methyl 12-(2-acetamido)dodecanoate] - 1,4,7,10-
tetraazacyclododecan 
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(L)-2-(2-Chloroacetamido)-3-phenylpropanoic acid 
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1,4,7-Tris (carboxymethyl)- 10-[(L)-2-(2-acetamido)-3-phenylpropanoic acid]- 1,4,7,10-
tetraazacyclododecan 
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(L)-Methyl-2-amino-3-phenylpropanoate 
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(L)-Methyl 2-(2-chloroacetamido)-3-phenylpropanoate 
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1,4,7-Tris (carboxymethyl)- 10-[(L)-methyl 2-(2-acetamido)-3-phenylpropanoate]- 1,4,7,10-
tetraazacyclododecan 
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Spectral Width (ppm):
(f1) 238.298     
Pulse Program:
ZGPG30
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Date:
18 Oct 2004
Document's Title:
H-nmr-dmpa1409
Spectrum Title:
PROTON128 D2O DO3A-
metylphenylalanin
Frequency (MHz):
(f1) 300.132     
Original Points Count:
(f1) 32768     
Actual Points Count:
(f1) 32768     
Acquisition Time (sec):
(f1) 5.3084     
Spectral Width (ppm):
(f1) 20.567     
Pulse Program:
ZG30
 
 
